Navigation Links
AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy
Date:10/12/2009

ng in the formation of functional protein. Positive long-term health effects of this approach have been demonstrated in animals.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan), especially diseases that are caused by one faulty gene. Currently, AMT has a product pipeline with nine products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AM
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Oct. 16—As in Alice,s journey through the looking-glass to ... in surprising and unexpected ways, including a new class ... As reported today in The Optical Society,s (OSA) new ... demonstrated, for the first time, a new type of ... instead reflects infrared light by using an unusual magnetic ...
(Date:10/17/2014)... Horsham, PA (PRWEB) October 17, 2014 ... is being called upon by health facilities around ... exposed patients are being treated. Among the many ... used includes Texas Health Presbyterian Hospital Dallas and ... Center. The state-of-the-art vapor-producing robots have been utilized ...
(Date:10/17/2014)... (PRWEB) October 17, 2014 The Europe ... additives market in Europe with analysis and forecast of ... Fuel Additives Market report, to get an idea of ... of the segmentation in the European fuel additives market, ... , http://www.micromarketmonitor.com/market/europe-fuel-additives-5379768082.html , Fuel additives are chemicals ...
(Date:10/17/2014)... The Middle East and Africa Location Based Services (LBS) market ... East and Africa with analysis and forecast of revenue. This ... to $3,403.1 million by 2019, at a CAGR of 38.5% ... the Middle East and Africa Location Based Services (LBS) market ... It also provides a glimpse of the market segmentation, and ...
Breaking Biology Technology:Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 3Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 5Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 6The Europe Fuel Additives Market is estimated to grow to $1,401.4 million by 2018 - New Report by MicroMarket Monitor 2The Europe Fuel Additives Market is estimated to grow to $1,401.4 million by 2018 - New Report by MicroMarket Monitor 3The Europe Fuel Additives Market is estimated to grow to $1,401.4 million by 2018 - New Report by MicroMarket Monitor 4The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 2The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 3The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 4
... CITY , Jan. 22 /PRNewswire-FirstCall/ - Æterna Zentaris ... late-stage drug development company specialized in oncology and endocrinology, today ... received a letter from the Listing Qualifications Department of The ... of its common shares had fallen below US$1.00 ...
... , Twenty leading US research ... benefits of NIH funding through the 2009 Recovery and Reinvestment ... In advance of the one-year anniversary of the Recovery ... of the nation,s leading research institutions, patient advocates and biomedical ...
... ... is excited to announce its latest product offering, PrescriberPRO Mobile. ,PrescriberPRO Mobile ... Solutions’ full database of over 1,000,000 medical prescribers. The application will provide names, ... the United States. , ...
Cached Biology Technology:Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price 2Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price 3A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs 2A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs 3Healthcare Data Solutions Announces New Mobile Application, PrescriberPRO Mobile 2Healthcare Data Solutions Announces New Mobile Application, PrescriberPRO Mobile 3
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology , ... announced the availability of the VeriLook Surveillance ... 3.0 provides real-time biometric face identification using live ... surveillance cameras. The new version not only identifies ... people from objects while they are moving through ...
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
(Date:10/14/2014)... – Scientists from The Scripps Research Institute (TSRI) have ... Health (NIH) to lead an investigation of Lassa fever ... Africa. The study aims to understand how Lassa fever ... others survive the inflection. , "The ultimate goal ... how Lassa fever virus causes disease and develop new ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... obesity and associated diseases -- and fiery debates about the ... identified a new genetic mechanism that controls the body,s fat-building ... treatments for obesity and type 2 diabetes, and it has ... dramatically cut health care costs. A research team led ...
... research developed by a scientist at The University ... selected for funding by a National Institutes of ... investigations. Valentin Dragoi, Ph.D., assistant professor of ... at Houston, has been awarded a four-year, $1.2 ...
... Calif.) Scientists at UC Santa Barbara have discovered a ... mechanism for delivery of nanoparticles into tissue. The results are ... of Sciences . "This work is important because when ... blood stream, but often doesn,t get into the tissue," said ...
Cached Biology News:UCF discovery could open door to obesity, diabetes treatments 2UT's Valentin Dragoi gets $1.2 million grant for groundbreaking approach to brain research 2UT's Valentin Dragoi gets $1.2 million grant for groundbreaking approach to brain research 3